Posts
- Category: Articles (continued)
- New test measures deadly protein in Huntington's disease patients' spinal fluid
- New therapeutic target identified for Huntington's disease
- New Therapies on the Horizon for Huntington's Disease
- New £9.1m contract with a top 10 global pharmaceutical company
- News from the Society for Neuroscience Annual Meeting: Gene Editing Techniques Show Promise in Silencing or Inhibiting the Mutant Huntington's Disease Gene
- NEWSHD.NET un'anno insieme
- NIH study advances understanding of movement control
- NOBEL PRIZE TO BRITON, JAPANESE FOR STEM CELL WORK
- Northwestern Medicine Launches Huntington's Disease Center
- NOTIZIARIO AICH - ROMA APRILE 2014
- Notiziario AICH - Roma Onlus Marzo-Aprile 2012
- NOTIZIARIO AICH ROMA DICEMBRE 2013
- NOTIZIARIO AICH – ROMA AGOSTO 2014
- Novel Gene Therapy Drug for Huntington's Disease
- Novel PET Biomarker May Detect Early Huntington's
- Novel RNAi Therapy Silences Mutated Huntington's Disease Gene and Reduces Symptoms
- Novel type of cell death in Huntington's disease may lead to effective new therapies
- Novità per la cura della malattia di Huntington
- Numerate Trains Its Computer-Aided Drug Design Platform On Huntington's Disease
- Nuova sperimentazione del PBT2 prodotto dalla Prana Biotech per la malattia di Huntington: notizie importanti
- Nuovo farmaco per la Malattia di Huntington sarà testato a Vancouver.
- Nutritional supplement slows Huntington’s
- Nuvilex reports breakthrough in stem cell research
- NZ scientists turn skin into brain cells
- Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
- Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824
- Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
- Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders
- Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
- Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
- Omeros Reports Additional Positive Results from OMS824 Program
- Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease
- Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
- On the Hunt for Huntington’s Disease Treatments in the New Millennium
- Oral feeding in Huntington’s disease: a guideline document for speech and language therapists
- Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
- Parkinson's, Huntington's disease research makes advances with stem cells: Discoveries
- PBT2 recommended for orphan designation in Europe
- Penn Biologists Identify a Key Enzyme Involved in Protecting Nerves From Degeneration
- Phosphodiesterase inhibitors: new HD drugs entering trials soon
- Possible role for Huntington’s gene discovered
- Postdoctoral Fellowship, Huntington's Disease
- Potential new treatments for depression uncovered by research into Huntington's
- Potential Therapeutic Target for Huntington’s Disease
- Potential Treatment for Huntington's Disease, Found Effective, Safe in Mice, Monkeys, Enters Clinical Testing
- Potential treatment for Huntington’s disease discovered by NUIG researchers
- Prana Alzheimer's disease data features at world leading conference
- Prana Announces Successful Phase 2 Results in Huntington Disease Trial
- Prana Biotechnology Investor Presentation and Audio Recording - Phase 2 HD trial
- Prana Completes Phase 2 Huntington Disease Trial with PBT2
Plugin by dagondesign.com
